Loading...
Market
Regulatory body blocks J&J acquisition of Intra-Cellular Therapies by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements from regulatory bodies like the FTC or SEC, financial news outlets
Story
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion at $132 Per Share, Marking Largest Biotech Deal in Over a Year
Jan 13, 2025, 02:49 PM
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc. for approximately $14.6 billion, marking the largest biotech deal in over a year. The acquisition, announced at the J.P. Morgan Healthcare Conference, involves a purchase price of $132 per share. Intra-Cellular, co-founded by Sharon Mates in 2002, is known for its drug Caplyta, which received FDA approval in December 2019. The deal comes amidst a flurry of biotech acquisitions, with Eli Lilly and GSK also announcing significant purchases of Scorpion Therapeutics and IDRx, respectively, during the same conference.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Acquisition completed • 25%
No official outcome by end of 2025 • 25%
Acquisition abandoned • 25%
Acquisition delayed • 25%
Acquisition Delayed • 25%
Acquisition Abandoned • 25%
Other Outcomes • 25%
Acquisition Completed • 25%
No • 50%
Yes • 50%
No change • 25%
Decrease • 25%
Increase by 0-10% • 25%
Increase by more than 10% • 25%